Avecho Biotechnology Management
Management criteria checks 4/4
Avecho Biotechnology's CEO is Paul Gavin, appointed in May 2020, has a tenure of 4.58 years. total yearly compensation is A$291.80K, comprised of 77.8% salary and 22.2% bonuses, including company stock and options. directly owns 0.34% of the company’s shares, worth A$32.58K. The average tenure of the management team and the board of directors is 4.6 years and 7.3 years respectively.
Key information
Paul Gavin
Chief executive officer
AU$291.8k
Total compensation
| CEO salary percentage | 77.8% |
| CEO tenure | 4.6yrs |
| CEO ownership | 0.3% |
| Management average tenure | 4.6yrs |
| Board average tenure | 7.3yrs |
Recent management updates
Recent updates
Companies Like Avecho Biotechnology (ASX:AVE) Are In A Position To Invest In Growth
Jan 13
Here's Why We're Watching Avecho Biotechnology's (ASX:AVE) Cash Burn Situation
May 31Avecho Biotechnology (ASX:AVE) Is In A Good Position To Deliver On Growth Plans
Nov 04We're Hopeful That Avecho Biotechnology (ASX:AVE) Will Use Its Cash Wisely
Jul 14We Think Avecho Biotechnology (ASX:AVE) Can Afford To Drive Business Growth
Mar 23We're Not Very Worried About Avecho Biotechnology's (ASX:AVE) Cash Burn Rate
Dec 08
CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Jun 30 2024 | n/a | n/a | -AU$3m |
| Mar 31 2024 | n/a | n/a | -AU$3m |
| Dec 31 2023 | AU$292k | AU$227k | -AU$3m |
| Sep 30 2023 | n/a | n/a | -AU$4m |
| Jun 30 2023 | n/a | n/a | -AU$4m |
| Mar 31 2023 | n/a | n/a | -AU$3m |
| Dec 31 2022 | AU$355k | AU$227k | -AU$2m |
| Sep 30 2022 | n/a | n/a | -AU$2m |
| Jun 30 2022 | n/a | n/a | -AU$2m |
| Mar 31 2022 | n/a | n/a | -AU$3m |
| Dec 31 2021 | AU$477k | AU$227k | -AU$3m |
| Sep 30 2021 | n/a | n/a | -AU$3m |
| Jun 30 2021 | n/a | n/a | -AU$3m |
| Mar 31 2021 | n/a | n/a | -AU$3m |
| Dec 31 2020 | AU$497k | AU$231k | -AU$3m |
| Sep 30 2020 | n/a | n/a | -AU$2m |
| Jun 30 2020 | n/a | n/a | -AU$2m |
| Mar 31 2020 | n/a | n/a | -AU$739k |
| Dec 31 2019 | AU$235k | AU$200k | AU$850k |
| Sep 30 2019 | n/a | n/a | AU$504k |
| Jun 30 2019 | n/a | n/a | AU$158k |
| Mar 31 2019 | n/a | n/a | -AU$2m |
| Dec 31 2018 | AU$231k | AU$200k | -AU$4m |
| Jun 30 2018 | n/a | n/a | -AU$6m |
| Mar 31 2018 | n/a | n/a | -AU$7m |
| Dec 31 2017 | AU$238k | AU$200k | -AU$9m |
Compensation vs Market: Paul's total compensation ($USD182.50K) is below average for companies of similar size in the Australian market ($USD291.73K).
Compensation vs Earnings: Paul's compensation has been consistent with company performance over the past year.
CEO
Paul Gavin
4.6yrs
Tenure
AU$291,796
Compensation
Dr. Paul Gavin, BSc (Hons), PhD serves as Chief Executive Officer of Avecho Biotechnology Limited (formerly known as Phosphagenics Limited) since May 01, 2020 and served as its Chief Scientific Officer unt...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Chief Executive Officer | 4.6yrs | AU$291.80k | 0.34% A$ 32.6k | |
| Chief Operating Officer | 4.6yrs | AU$242.70k | 0.35% A$ 33.3k | |
| Company Secretary & CFO | 6yrs | no data | no data |
4.6yrs
Average Tenure
Experienced Management: AVE's management team is considered experienced (4.6 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Independent Director | 9.7yrs | AU$65.32k | 0.11% A$ 10.0k | |
| Independent Non-Executive Chairman | 9.7yrs | AU$115.10k | 0.31% A$ 29.5k | |
| Chairman of Scientific Advisory Board | no data | no data | no data | |
| Independent Non-Executive Director | 4.9yrs | AU$65.32k | 0.053% A$ 5.0k | |
| Non-Executive Director | less than a year | no data | no data |
7.3yrs
Average Tenure
62.5yo
Average Age
Experienced Board: AVE's board of directors are considered experienced (7.3 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/21 12:47 |
| End of Day Share Price | 2024/12/20 00:00 |
| Earnings | 2024/06/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Avecho Biotechnology Limited is covered by 4 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Dennis Hulme | APP Securities Pty Ltd. |
| Scott Power | Morgans Financial Limited |
| David Stanton | Nomura Securities Co. Ltd. |